No abstract

No abstract

One of the most serious problems of our times is the protection of the environment. Within this framework, a significant contribution is made by environmental organisations in raising awareness among the public in order to resolve a great number of environmental concerns. The most important tool for the achievement of this goal is the implementation of public relations programmes through a public relations officer, as fragmented actions carried out by any other member of the organisation are considered ineffective. Consequently, the basic question in this case, lies in identifying the characteristics of the organisations that do actually operate in an effective manner. Data concerning environmental organisations was gathered through a structured questionnaire and processed using the non-linear principal components analysis technique from the statistical program SPSS. The main result of this research was that those environmental organisations that do have a public relations officer are usually those with the greatest amount of members.

ABSTRACT:The oxidative biotransformation of the anticancer drug 7-hydroxy- 2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthra[1,9-cd]pyrazol-6(2H)-one dihydrochloride (losoxantrone, CI-941) after incubation of primary cultures of rat hepatocytes has been investigated. The structures of twelve losoxantrone metabolites have been elucidated by means of highperformance liquid chromatography-mass spectometry, tandem mass spectrometry, and two-dimensional NMR. In these mammalian hepatocytes, the CI-941 biotransformation includes a monohydroxylation of the phenolic substructure of the CI-941-chromophore via cytochrome P450 catalysis, resulting in metabolites having an orthoand para-hydroquinonoid substructure, respectively. The identification of a glutathione conjugate as a follow-up metabolite confirms the oxidative activation of the ortho-hydroxylated losoxantrone metabolite. The oxidative activation establishes the ability of CI-941 to form covalent bonds to intracellular nucleophilic targets. Furthermore, the CI-941 metabolism was shown to be extremely suppressed in rat hepatocytes incubated with metyrapone. In contrast to these results, human tumor HepG2 cells did not show any CI-941 biotransformation after incubation., is a member of the novel class of anthrapyrazole anticancer agents. This cytostatic compound is derived from anthracyclines (e.g., doxorubicin and daunorubicin) and mitoxantrone by chromophore modification of the anthracene-9,10-dione unit. In clinical trials (phase I and II), losoxantrone has been shown to be the most powerful anthrapyrazole. It was developed with the intention of diminishing the cardiotoxicity associated with anthracene-9,10-dione drugs. The cardiotoxicity represents the dosis-limiting side effect and is induced by free radicals created during the biotransformation of anthraquinonoid antitumor agents (Murdock et al., 1979;Smith, 1983;Zee-Cheng and Cheng, 1983) (Fig. 1).Both the synthetic preparation and the exceptional in vivo anticancer activity of losoxantrone are well known (Lown, 1983;Showalter et al., 1987;Reszka et al., 1988;Beylin et al., 1989;Fry, 1991;Calvert et al., 1994;Zhang et al., 1994). Several clinical studies of combination regimens with losoxantrone and paclitaxel in patients with advanced breast cancer were recently completed (Kaufman et al., 1998(Kaufman et al., , 1999Diab et al., 1999). Furthermore, the results of a phase II clinical trail in hormone-refractory metastatic prostate cancer were published (Huan et al., 2000).The antitumor activity of losoxantrone, among other biochemical effects against tumor cells, is based on inhibiting the enzyme topoisomerase II (Fry, 1991;Leteurtre et al., 1994). Although numerous studies analyzing the pharmacokinetic behavior of the drug under various conditions were published, the metabolism of anthrapyrazole CI-941 is almost unknown until now. Only a small part of the CI-941 biotransformation, proved by metabolites in human urine Richards and Sun, 1995) and feces (Joshi et al., 2001), was ...

No abstract

The multistep synthesis and negative ion-ESI fragmentation pattern of [methyl-D(3)](2)hypericin (1-D(6)) is described. The application of 1-d(6) as internal standard for the quantification of hypericin (1) in the ng mL(-1) range in human plasma by isotope-dilution LC-MS is demonstrated. The hypericin-containing plasma samples are spiked with 1-D(6), deproteinized and extracted with ethyl acetate. The extracts are injected into a HPLC-ESI-ion-trap system and the mass-separated negative ions from 1 and 1-D(6) are analysed. From their intensities linear standard curves over the concentration range from 1 to 10 ng mL(-1) are obtained. Accuracy, precision and recovery are discussed.

No abstract